{"id":1109,"date":"2022-02-15T11:33:36","date_gmt":"2022-02-15T11:33:36","guid":{"rendered":"https:\/\/mabion.vipserv.org\/?page_id=1109"},"modified":"2022-04-28T13:11:25","modified_gmt":"2022-04-28T13:11:25","slug":"press-releases","status":"publish","type":"page","link":"https:\/\/old123.mabion.eu\/en\/press-releases\/","title":{"rendered":"Press releases"},"content":{"rendered":"<div class=\"M-content-text      \"><div class=\"M-content-text__col --has-text \"><div class=\"M-text-default\"><h1 class=\"M-text-size-26px M-text-font-KronaOne\">Press releases<\/h1><\/div><\/div><\/div>\n\n<div class=\"M-reports\">\r\n    <div class=\"M-reports__tabs\">\r\n        <ul class=\"M-reports__tabs__inner\">\r\n                                    <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2022_a\"\r\n                    data-id=\"2022_a\">2022<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2021_a\"\r\n                    data-id=\"2021_a\">2021<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2020_a\"\r\n                    data-id=\"2020_a\">2020<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2019_a\"\r\n                    data-id=\"2019_a\">2019<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2018_a\"\r\n                    data-id=\"2018_a\">2018<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2017_a\"\r\n                    data-id=\"2017_a\">2017<\/a><\/li>\r\n                                                                        <li class=\"M-reports__tabs__item\"><a class=\"M-reports__tabs__link --is-active\"\r\n                    href=\"#2016_a\"\r\n                    data-id=\"2016_a\">2016<\/a><\/li>\r\n                                                        <\/ul>\r\n    <\/div>\r\n    <div class=\"M-content-table__outher\">\r\n        <table class=\"M-content-table\">\r\n            <colgroup>\r\n                                                <col class=\"M-content-table__col-date\">\r\n                                                                <col class=\"M-content-table__col-default\">\r\n                                                                <col class=\"M-content-table__col-action\">\r\n                                            <\/colgroup>\r\n            <thead>\r\n                <tr>\r\n                                                                                                                                                                                                                                                                                    <\/tr>\r\n            <\/thead>\r\n                                                    <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2022_a\">\r\n                                                <tr>\r\n                                                            <td><b>21\/04\/2022<\/b><\/td>\r\n                                                                                <td>Mabion reviews breakthrough year 2021 and announces increased growth in 2022<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/04\/Press-Release-Yearly-Results_Mabion.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/04\/Press-Release-Yearly-Results_Mabion.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>28\/01\/2022<\/b><\/td>\r\n                                                                                <td>Mabion joins the Great Orchestra of Christmas Charity (WO\u015aP) and donates headquarters visit for auction at 30th Grand Finale <\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/280122_Mabion-joins-the-Great-Orchestra-of-Christmas-Charity-WOS\u0301P-and-donates-headquarters-visit-for-auction-at-30th-Grand-Finale.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/280122_Mabion-joins-the-Great-Orchestra-of-Christmas-Charity-WOS\u0301P-and-donates-headquarters-visit-for-auction-at-30th-Grand-Finale.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>18\/01\/2022<\/b><\/td>\r\n                                                                                <td>Mabion and Novavax expand scope of collaboration  to include additional key elements of the COVID-19 vaccine manufacturing process <\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/Mabion-i-Novavax-poszerzaja\u0328-zakres-wspo\u0301lpracy-o-dodatkowe-elementy-en.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/Mabion-i-Novavax-poszerzaja\u0328-zakres-wspo\u0301lpracy-o-dodatkowe-elementy-en.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2021_a\">\r\n                                                <tr>\r\n                                                            <td><b>23\/12\/2021<\/b><\/td>\r\n                                                                                <td>Mabion executes agreement with Novavax and produces  first full batch of antigen for COVID-19 vaccine  <\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/20211222-Pierwsza-pelna-seria-antygenu-en.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/20211222-Pierwsza-pelna-seria-antygenu-en.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>20\/12\/2021<\/b><\/td>\r\n                                                                                <td>Novavax COVID-19 vaccine receives positive recommendation  from European Medicines Agency and approval for use in European Union countries. Mabion executes Novavax contract as planned and in full agreement with partner.<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/Informacja-prasowa-Mabion-20.12.2021-en.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/03\/Informacja-prasowa-Mabion-20.12.2021-en.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>8\/10\/2021<\/b><\/td>\r\n                                                                                <td>Mabion Announces Commercial Manufacturing Agreement for Novavax COVID-19 Vaccine<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_announces_commercial_manufacturing_agreement_for_novavax_covid-19_vaccine.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_announces_commercial_manufacturing_agreement_for_novavax_covid-19_vaccine.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>03\/03\/2021<\/b><\/td>\r\n                                                                                <td>Mabion and the Polish Development Fund signed a preliminary agreement on capital support for the production of a vaccine for COVID-19<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210303_mabion_and_polish_development_fund_signed_a_preliminary_agreement_on_capital_support_for_the_production_of_a_vaccine_for_covid-19_press_release.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210303_mabion_and_polish_development_fund_signed_a_preliminary_agreement_on_capital_support_for_the_production_of_a_vaccine_for_covid-19_press_release.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>03\/03\/2021<\/b><\/td>\r\n                                                                                <td>Mabion Announces signing an Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210303_mabion_announces_agreement_with_novavax_for_large-scale_vaccine_manufacturing_feasibility_assessment_press_release-1.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210303_mabion_announces_agreement_with_novavax_for_large-scale_vaccine_manufacturing_feasibility_assessment_press_release-1.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>22\/02\/2021<\/b><\/td>\r\n                                                                                <td>Mabion implements next stage of its financial strategy &#8211; the Company convenes EGSM to conduct a public share offering and raise up to PLN 200 million to complete the development and market launch of MabionCD20<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210222_mabion_zwolanie_nwza_informacja_prasowa_eng_final.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210222_mabion_zwolanie_nwza_informacja_prasowa_eng_final.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>28\/01\/2021<\/b><\/td>\r\n                                                                                <td>Mabion S.A. updates its financial strategy, seeks a strategic investor and convenes a GSM to pass a resolution on issue of shares<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210128_mabion_sa_updates_its_financial_strategy_and_looks_for_a_strategic_investor_en_final.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20210128_mabion_sa_updates_its_financial_strategy_and_looks_for_a_strategic_investor_en_final.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2020_a\">\r\n                                                <tr>\r\n                                                            <td><b>29\/10\/2020<\/b><\/td>\r\n                                                                                <td>Mabion and Vaxine enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20200914_mabion_cooperation_vaxine_press_release.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20200914_mabion_cooperation_vaxine_press_release.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>30\/07\/2020<\/b><\/td>\r\n                                                                                <td>Mabion initiates the national and regional PCT phases of the patent application for the use of MabionCD20 in the treatment of Multiple Sclerosis (MS)<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20200730_mabion_zlozenie_wnioskow_patentowych_mabionms_eng.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20200730_mabion_zlozenie_wnioskow_patentowych_mabionms_eng.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>15\/07\/2020<\/b><\/td>\r\n                                                                                <td>Company receives a loan from a shareholder for the repayment of loan from Santander bank<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_received_a_loan_from_a_shareholder_for_the_repayment_of_credit_in_santander_bank.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_received_a_loan_from_a_shareholder_for_the_repayment_of_credit_in_santander_bank.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>19\/05\/2020<\/b><\/td>\r\n                                                                                <td>The Management Board and the Supervisory Board of Mabion S.A. in favour of share issue to support the next phase of work on the registration of MabionCD20 in several regulated markets<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/the_management_board_and_the_supervisory_board_of_mabion_sa_in_favour_of_share_issue_to_support_the_next_phase_of_work_in_the_registration_of_mabioncd20_in_several_regulated_markets.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/the_management_board_and_the_supervisory_board_of_mabion_sa_in_favour_of_share_issue_to_support_the_next_phase_of_work_in_the_registration_of_mabioncd20_in_several_regulated_markets.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2019_a\">\r\n                                                <tr>\r\n                                                            <td><b>12\/11\/2019<\/b><\/td>\r\n                                                                                <td>Mabion had submitted answers to the second round of questions by the European Medicines Agency (EMA) received as part of the Day 180 stage of the registration procedure for MabionCD20\u200b<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20191112_mabion__eng.pdf\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20191112_mabion__eng.pdf\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2018_a\">\r\n                                                <tr>\r\n                                                            <td><b>10\/2018<\/b><\/td>\r\n                                                                                <td>Mabion submits a second registration application to EMA for the MabionCD20 d<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>06\/2018<\/b><\/td>\r\n                                                                                <td>Mabion S.A. completes marketing authorisation application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>03\/2018<\/b><\/td>\r\n                                                                                <td>Mabion Announces a USD$51.0 Million Private Placement with European and US Investors<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2017_a\">\r\n                                                <tr>\r\n                                                            <td><b>04\/09\/2017<\/b><\/td>\r\n                                                                                <td>Mabion S.A. with a new innovative indication in the treatment of multiple sclerosis for MabionCD20<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>31\/03\/2017<\/b><\/td>\r\n                                                                                <td>Mabion S.A. adopts a strategy plan concerning development of medicinal products<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                                                        <!-- <\/tbody> -->\r\n                                        <tbody data-id=\"2016_a\">\r\n                                                <tr>\r\n                                                            <td><b>14\/12\/2016<\/b><\/td>\r\n                                                                                <td>Mabion S.A. faces international challenges and welcomes new President of the Board<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_sa_faces_international_challenges_and_welcomes_new_president_of_the_board.docx\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion_sa_faces_international_challenges_and_welcomes_new_president_of_the_board.docx\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>10\/11\/2016<\/b><\/td>\r\n                                                                                <td>Mabion S.A. signs supply and commercialization agreement with Mylan regarding MabionCD20 for EU markets<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                    <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>22\/06\/2016<\/b><\/td>\r\n                                                                                <td>Mabion S.A. is on track for completing the MabionCD20 clinical programme and signing a partnering contract <\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20160622_mabion_sa_is_on_track_for_completing_the_mabioncd20_clinical_programme_and_signing_a_partnering_contract__.doc\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/20160622_mabion_sa_is_on_track_for_completing_the_mabioncd20_clinical_programme_and_signing_a_partnering_contract__.doc\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <tr>\r\n                                                            <td><b>22\/03\/2016<\/b><\/td>\r\n                                                                                <td>Biosimilar rituximab \u2013 many have started \u2013 only a few will succeed<\/td>\r\n                                                                                <td class=\" M-content-table__col-action\">\r\n                                                                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/2016_04_01_biosimilar_rituximab__many_have_started__only_a_few_will_succeed.doc\" target=\"_blank\"\r\n                            title=\"Open and read.\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-magnifier.svg\"\r\n                                alt=\"\"><\/a>\r\n                        <a href=\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/2016_04_01_biosimilar_rituximab__many_have_started__only_a_few_will_succeed.doc\" title=\"Download\"\r\n                            download=\"\"><img decoding=\"async\"\r\n                                src=\"https:\/\/old123.mabion.eu\/wp-content\/themes\/mabion\/resource\/gfx\/ico-download.svg\"\r\n                                alt=\"\"><\/a>\r\n                                            <\/td>\r\n                                                        <\/tr>\r\n                                                <!-- <\/tbody> -->\r\n                        <\/table>\r\n    <\/div>\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-1109","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Press releases - Mabion<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/old123.mabion.eu\/en\/press-releases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press releases - Mabion\" \/>\n<meta property=\"og:url\" content=\"https:\/\/old123.mabion.eu\/en\/press-releases\/\" \/>\n<meta property=\"og:site_name\" content=\"Mabion\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-28T13:11:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/old123.mabion.eu\/#organization\",\"name\":\"Mabion\",\"url\":\"https:\/\/old123.mabion.eu\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/old123.mabion.eu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion-logo__black.svg\",\"contentUrl\":\"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion-logo__black.svg\",\"caption\":\"Mabion\"},\"image\":{\"@id\":\"https:\/\/old123.mabion.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/old123.mabion.eu\/#website\",\"url\":\"https:\/\/old123.mabion.eu\/\",\"name\":\"Mabion\",\"description\":\"Just another WordPress site\",\"publisher\":{\"@id\":\"https:\/\/old123.mabion.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/old123.mabion.eu\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/old123.mabion.eu\/en\/press-releases\/\",\"url\":\"https:\/\/old123.mabion.eu\/en\/press-releases\/\",\"name\":\"Press releases - Mabion\",\"isPartOf\":{\"@id\":\"https:\/\/old123.mabion.eu\/#website\"},\"datePublished\":\"2022-02-15T11:33:36+00:00\",\"dateModified\":\"2022-04-28T13:11:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/old123.mabion.eu\/en\/press-releases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/old123.mabion.eu\/en\/press-releases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/old123.mabion.eu\/en\/press-releases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Strona g\u0142\u00f3wna\",\"item\":\"https:\/\/old123.mabion.eu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press releases\"}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press releases - Mabion","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/old123.mabion.eu\/en\/press-releases\/","og_locale":"en_US","og_type":"article","og_title":"Press releases - Mabion","og_url":"https:\/\/old123.mabion.eu\/en\/press-releases\/","og_site_name":"Mabion","article_modified_time":"2022-04-28T13:11:25+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/old123.mabion.eu\/#organization","name":"Mabion","url":"https:\/\/old123.mabion.eu\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/old123.mabion.eu\/#\/schema\/logo\/image\/","url":"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion-logo__black.svg","contentUrl":"https:\/\/old123.mabion.eu\/wp-content\/uploads\/2022\/02\/mabion-logo__black.svg","caption":"Mabion"},"image":{"@id":"https:\/\/old123.mabion.eu\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/old123.mabion.eu\/#website","url":"https:\/\/old123.mabion.eu\/","name":"Mabion","description":"Just another WordPress site","publisher":{"@id":"https:\/\/old123.mabion.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/old123.mabion.eu\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/old123.mabion.eu\/en\/press-releases\/","url":"https:\/\/old123.mabion.eu\/en\/press-releases\/","name":"Press releases - Mabion","isPartOf":{"@id":"https:\/\/old123.mabion.eu\/#website"},"datePublished":"2022-02-15T11:33:36+00:00","dateModified":"2022-04-28T13:11:25+00:00","breadcrumb":{"@id":"https:\/\/old123.mabion.eu\/en\/press-releases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/old123.mabion.eu\/en\/press-releases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/old123.mabion.eu\/en\/press-releases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Strona g\u0142\u00f3wna","item":"https:\/\/old123.mabion.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Press releases"}]}]}},"_links":{"self":[{"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/pages\/1109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/comments?post=1109"}],"version-history":[{"count":5,"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/pages\/1109\/revisions"}],"predecessor-version":[{"id":8291,"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/pages\/1109\/revisions\/8291"}],"wp:attachment":[{"href":"https:\/\/old123.mabion.eu\/en\/wp-json\/wp\/v2\/media?parent=1109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}